Full-Time

Manager Software Development & Engineering

Industrial IoT

Posted on 10/30/2025

Amgen

Amgen

10,001+ employees

Biotech company creating biologic medicines

No salary listed

Hyderabad, Telangana, India

In Person

Category
Software Engineering (3)
, ,
Required Skills
Kotlin
Kubernetes
Rust
Microsoft Azure
Python
JavaScript
React.js
MySQL
NoSQL
Git
Node.js
SQL
Java
Postgres
Docker
TypeScript
C#
AWS
Go
Scala
Jenkins
iOS/Swift
Vue.js
Redis
MongoDB
REST APIs
Flask
C/C++
DevOps
AngularJS
Spring
Django
Google Cloud Platform
Hibernate
Requirements
  • Doctorate degree
  • Master's degree
  • Bachelor's degree and 8 to 13 years of experience in software development, managing engineering or development teams, preferably in an industrial or IoT environment
Responsibilities
  • Lead the IoT Development Team: Manage a team of software developers, ensuring that workloads are balanced, project achievements are met, and individual contributors are supported in their professional growth.
  • Project Management: Oversee planning, execution, and delivery of industrial IoT projects. Coordinate team activities, manage timelines, and ensure alignment of resources to meet project goals.
  • Technical Oversight: Provide guidance on software development standard methodologies, code quality, and fixing. Support the team in implementing features, resolving technical challenges, and adhering to architectural standards.
  • Collaboration: Work in partnership with Operations, Quality, Automation, and IT teams, building strong multi-functional relationships to ensure software solutions meet business needs and align with regulatory requirements.
  • Requirements Gathering: Engage with collaborators to define project scope, collect user requirements, and translate them into actionable development plans and technical specifications.
  • Software Development Lifecycle Management: Monitor all phases of SDLC, from design and build through testing, deployment, and support. Ensure proper documentation, validation protocols, and training materials are developed and maintained.
  • Quality Assurance & Compliance: Champion standards for code quality, data integrity, cybersecurity, and regulatory compliance, including GxP and other industry requirements.
  • Mentorship & Talent Development: Mentor engineers within the team, fostering their technical growth, collaboration skills, and commitment to continuous improvement.
  • Incident Management: Act as the primary customer concern point for technical issues affecting the team's work, coordinating incident response and root cause analysis as needed.
  • Continuous Improvement: Find opportunities for team and process improvement. Encourage adoption of new tools, technologies, and practices to enhance productivity and code quality.
  • Change Management: Support change management initiatives to facilitate the successful adoption of new software systems across industrial sites.
  • External Collaboration: Coordinate with contractors, partners, and external vendors engaged in IoT projects, ensuring consistent communication and alignment with internal standards.
Desired Qualifications
  • Experience with industrial automation systems and advanced IoT modules.
  • Familiarity with integrating IoT platforms with SCADA, data historians, and enterprise systems.
  • Exposure to ISA-95 standards, data lakes, and digital manufacturing initiatives including AI/ML for manufacturing data.
  • Experience working with global, matrixed teams and external vendors.
  • Professional certifications in IoT, software development, or project management.
  • Communication: Excellent verbal and written communication skills, able to clearly articulate technical concepts and foster strong team relationships.
  • Teamwork: Collaborative approach to problem solving, with a commitment to building trust and respect within the team and across departments.
  • Initiative: Self-motivated, proactive, and enthusiastic about getting results and supporting team success.
  • Analytical Thinking: Strong analytical and fixing abilities, with attention to detail and a commitment to root cause analysis.
  • Adaptability: Ability to manage multiple priorities and adapt to changing project requirements in a dynamic, fast-paced environment.
  • Leadership: Experience mentoring and developing engineering talent, with a passion for building hard-working teams and a culture of continuous improvement.

Amgen develops medicines that treat serious illnesses by using biologic therapies made from living cells. These therapies are designed to target specific disease processes, such as cancer, cardiovascular disease, and autoimmune conditions, and are produced through biotechnology methods that create proteins or antibodies. Amgen’s products are sold to patients and healthcare providers worldwide, with revenue funding ongoing research and development to discover new treatments. The company stands out by focusing on biologic medicines at a large scale and maintaining a steady pipeline of potential therapies across multiple disease areas, supported by global manufacturing and a commitment to bringing therapies to patients. Its goal is to improve patient outcomes by discovering and delivering new, effective treatments while reinvesting a significant portion of earnings into research and development.

Company Size

10,001+

Company Stage

IPO

Headquarters

Thousand Oaks, California

Founded

1980

Simplify Jobs

Simplify's Take

What believers are saying

  • Tarlatamab wins China NMPA approval May 2026 for $2B+ sales potential.
  • Q1 2026 revenues hit $8.6B with 16 brands posting double-digit growth.
  • Zai Lab partners on DLL3-ADC plus IMDELLTRA for SCLC trials.

What critics are saying

  • Prolia sales drop 34% to $727M from biosimilar competition in Q1 2026.
  • FDA warns Tavneos causes liver injuries, proposes approval withdrawal.
  • Horizon drugs Tepezza, Uplizna, Krystexxa underperform 19 months post-acquisition.

What makes Amgen unique

  • Amgen's BiTE platform establishes IMDELLTRA as second-line SCLC standard.
  • MariTide advances in Phase III obesity trials with monthly dosing.
  • UPLIZNA surges 73% post-IgG4 and gMG approvals in 2025.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Professional Development Budget

Conference Attendance Budget

Company News

Yahoo Finance
Apr 10th, 2026
Amgen's lung cancer drug tarlatamab wins China approval, seen as $2B+ opportunity

Amgen's lung cancer drug tarlatamab has received approval from China's National Medical Products Administration, according to its development partner BeOne Medicines. The drug is a targeted immunotherapy for adults with extensive-stage small cell lung cancer that has progressed despite chemotherapy. Sold as Imdelltra in the US, tarlatamab is a bispecific antibody designed to connect cancer cells with immune cells, enabling the body's immune system to destroy the cancer. Neither Amgen nor Hong Kong-listed BeOne provided details on launch date or pricing for the Chinese market. Wall Street analysts estimate tarlatamab could generate annual sales exceeding $2 billion for Amgen.

Yahoo Finance
Apr 3rd, 2026
Amgen faces Tavneos liver injury warning as Zai Lab oncology collaboration expands IMDELLTRA pipeline

Amgen faces fresh safety concerns after the FDA warned of severe liver injuries, including vanishing bile duct syndrome, linked to Tavneos (avacopan) in late March 2026. The development adds regulatory risk to the company's investment profile. Separately, Zai Lab announced a global collaboration with Amgen to test its DLL3-targeting ADC alongside Amgen's IMDELLTRA in extensive-stage small cell lung cancer, underscoring the company's ongoing oncology expansion through external partnerships. Amgen's narrative projects $37.4 billion revenue and $8.2 billion earnings by 2028, requiring 2.3% yearly revenue growth. However, pessimistic analysts model revenues slipping to $34.4 billion with earnings near $5.2 billion, reflecting concerns around pricing pressure, biosimilar competition and rising research and development spend alongside the new safety issues.

Yahoo Finance
Mar 30th, 2026
Amgen stock up 24% since Jim Cramer's June recommendation, beats earnings estimates

Amgen, one of the world's largest pharmaceutical companies, has seen its shares rise 24% since Jim Cramer discussed the stock on Mad Money in June 2025. The company is currently developing the weight loss drug MariTide. Amgen's shares jumped 7.5% in November 2025 after posting third-quarter results that beat analyst expectations, with $9.6 billion in revenue and $5.64 earnings per share against forecasts of $8.98 billion and $5.04 respectively. In February 2026, shares rose 8% following fourth-quarter earnings that also exceeded estimates. Cramer expressed cautious optimism about the biotech company, noting its mid-single-digit earnings growth and potential upside from its GLP-1 drug development. Whilst calling Eli Lilly his preferred GLP-1 play, Cramer said investors "could do a lot worse than Amgen" for a bargain option.

Yahoo Finance
Mar 25th, 2026
Wells Fargo lifts Amgen price target to $390, cites $20B myasthenia gravis market potential by 2036

Wells Fargo has raised its price target on Amgen to $390 from $375, maintaining an Equal Weight rating. The firm cited emerging therapies including CD20, BAFF/APRIL and next-generation complement inhibitors as potential drivers that could expand the generalized myasthenia gravis market threefold over the next decade, potentially reaching $15 billion in US sales and $20 billion globally by 2036. Separately, Jefferies initiated coverage on Amgen with a Hold rating and $350 price target on 10 March, noting the stock has gained approximately 35% over the past six months. Last month, Amgen reported fourth-quarter adjusted earnings per share of $5.29, beating the $4.76 consensus estimate, on revenue of $9.9 billion versus $9.45 billion expected.

Yahoo Finance
Mar 15th, 2026
Amgen joins TrumpRx discount scheme and lifts dividend to $2.52 per share

Amgen has announced a $2.52 per-share second-quarter dividend and joined the government-run TrumpRx platform to offer discounted drugs including Amjevita, Aimovig and Repatha. The company is also preparing for its 11 March presentation at the Leerink Global Healthcare Conference in Miami. The moves come alongside double-digit revenue and earnings per share growth in 2025 and advances in obesity and oncology programmes. However, the TrumpRx discounting could pressure net pricing as Amgen invests heavily in late-stage trials and manufacturing expansion. Amgen's narrative projects $37.4 billion revenue and $8.2 billion earnings by 2028, requiring 2.3% yearly revenue growth. Some analysts see a tougher outlook, with revenue potentially drifting towards $34.4 billion and earnings around $5.2 billion.

INACTIVE